|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CAMK2N1 |
Gene summary for CAMK2N1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CAMK2N1 | Gene ID | 55450 |
| Gene name | calcium/calmodulin dependent protein kinase II inhibitor 1 | |
| Gene Alias | PRO1489 | |
| Cytomap | 1p36.12 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q7Z7J9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55450 | CAMK2N1 | GSM4909285 | Human | Breast | IDC | 3.78e-02 | -1.77e-01 | 0.21 |
| 55450 | CAMK2N1 | GSM4909286 | Human | Breast | IDC | 1.03e-04 | -2.03e-01 | 0.1081 |
| 55450 | CAMK2N1 | GSM4909287 | Human | Breast | IDC | 4.38e-07 | -2.14e-01 | 0.2057 |
| 55450 | CAMK2N1 | GSM4909290 | Human | Breast | IDC | 1.81e-04 | -2.14e-01 | 0.2096 |
| 55450 | CAMK2N1 | GSM4909291 | Human | Breast | IDC | 1.25e-11 | 5.38e-01 | 0.1753 |
| 55450 | CAMK2N1 | GSM4909293 | Human | Breast | IDC | 8.37e-06 | 2.98e-01 | 0.1581 |
| 55450 | CAMK2N1 | GSM4909294 | Human | Breast | IDC | 3.10e-02 | 2.50e-01 | 0.2022 |
| 55450 | CAMK2N1 | GSM4909297 | Human | Breast | IDC | 5.90e-04 | 3.04e-01 | 0.1517 |
| 55450 | CAMK2N1 | GSM4909298 | Human | Breast | IDC | 3.35e-09 | 3.32e-01 | 0.1551 |
| 55450 | CAMK2N1 | GSM4909306 | Human | Breast | IDC | 1.27e-02 | 2.55e-01 | 0.1564 |
| 55450 | CAMK2N1 | GSM4909307 | Human | Breast | IDC | 2.07e-03 | -1.80e-01 | 0.1569 |
| 55450 | CAMK2N1 | GSM4909308 | Human | Breast | IDC | 1.11e-03 | -2.07e-01 | 0.158 |
| 55450 | CAMK2N1 | GSM4909311 | Human | Breast | IDC | 6.00e-06 | -9.27e-02 | 0.1534 |
| 55450 | CAMK2N1 | GSM4909317 | Human | Breast | IDC | 2.93e-09 | 3.02e-01 | 0.1355 |
| 55450 | CAMK2N1 | GSM4909319 | Human | Breast | IDC | 9.19e-07 | -1.63e-01 | 0.1563 |
| 55450 | CAMK2N1 | GSM4909321 | Human | Breast | IDC | 2.64e-07 | 3.73e-01 | 0.1559 |
| 55450 | CAMK2N1 | brca2 | Human | Breast | Precancer | 6.22e-04 | 1.16e-01 | -0.024 |
| 55450 | CAMK2N1 | brca3 | Human | Breast | Precancer | 3.00e-04 | 1.62e-01 | -0.0263 |
| 55450 | CAMK2N1 | NCCBC14 | Human | Breast | DCIS | 3.01e-23 | 8.46e-01 | 0.2021 |
| 55450 | CAMK2N1 | NCCBC5 | Human | Breast | DCIS | 2.16e-03 | 3.30e-01 | 0.2046 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
| GO:00342849 | Breast | Precancer | response to monosaccharide | 29/1080 | 225/18723 | 4.19e-05 | 9.00e-04 | 29 |
| GO:00097439 | Breast | Precancer | response to carbohydrate | 31/1080 | 253/18723 | 6.15e-05 | 1.25e-03 | 31 |
| GO:00425938 | Breast | Precancer | glucose homeostasis | 31/1080 | 258/18723 | 8.89e-05 | 1.69e-03 | 31 |
| GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
| GO:00335008 | Breast | Precancer | carbohydrate homeostasis | 31/1080 | 259/18723 | 9.56e-05 | 1.79e-03 | 31 |
| GO:00097469 | Breast | Precancer | response to hexose | 27/1080 | 219/18723 | 1.61e-04 | 2.69e-03 | 27 |
| GO:00097498 | Breast | Precancer | response to glucose | 25/1080 | 212/18723 | 5.46e-04 | 7.00e-03 | 25 |
| GO:00016787 | Breast | Precancer | cellular glucose homeostasis | 21/1080 | 172/18723 | 9.38e-04 | 1.06e-02 | 21 |
| GO:00713337 | Breast | Precancer | cellular response to glucose stimulus | 19/1080 | 151/18723 | 1.12e-03 | 1.23e-02 | 19 |
| GO:00713228 | Breast | Precancer | cellular response to carbohydrate stimulus | 20/1080 | 163/18723 | 1.15e-03 | 1.26e-02 | 20 |
| GO:00713317 | Breast | Precancer | cellular response to hexose stimulus | 19/1080 | 153/18723 | 1.31e-03 | 1.39e-02 | 19 |
| GO:00713267 | Breast | Precancer | cellular response to monosaccharide stimulus | 19/1080 | 154/18723 | 1.42e-03 | 1.48e-02 | 19 |
| GO:00512229 | Breast | Precancer | positive regulation of protein transport | 31/1080 | 303/18723 | 1.44e-03 | 1.50e-02 | 31 |
| GO:00507086 | Breast | Precancer | regulation of protein secretion | 28/1080 | 268/18723 | 1.76e-03 | 1.74e-02 | 28 |
| GO:00158336 | Breast | Precancer | peptide transport | 27/1080 | 264/18723 | 2.84e-03 | 2.49e-02 | 27 |
| GO:00900875 | Breast | Precancer | regulation of peptide transport | 22/1080 | 202/18723 | 3.14e-03 | 2.65e-02 | 22 |
| GO:00513489 | Breast | Precancer | negative regulation of transferase activity | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
| GO:00300736 | Breast | Precancer | insulin secretion | 21/1080 | 195/18723 | 4.38e-03 | 3.42e-02 | 21 |
| GO:00716926 | Breast | Precancer | protein localization to extracellular region | 34/1080 | 368/18723 | 4.65e-03 | 3.58e-02 | 34 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CAMK2N1 | SNV | Missense_Mutation | novel | c.203N>C | p.Lys68Thr | p.K68T | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.563) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CAMK2N1 | SNV | Missense_Mutation | novel | c.196N>A | p.Val66Met | p.V66M | Q7Z7J9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.706) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CAMK2N1 | SNV | Missense_Mutation | novel | c.185G>T | p.Arg62Met | p.R62M | Q7Z7J9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| CAMK2N1 | SNV | Missense_Mutation | c.113N>G | p.Ala38Gly | p.A38G | Q7Z7J9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
| CAMK2N1 | SNV | Missense_Mutation | c.219N>T | p.Lys73Asn | p.K73N | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
| CAMK2N1 | SNV | Missense_Mutation | novel | c.195N>A | p.Asp65Glu | p.D65E | Q7Z7J9 | protein_coding | tolerated_low_confidence(0.57) | benign(0.005) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
| CAMK2N1 | SNV | Missense_Mutation | c.95N>A | p.Thr32Asn | p.T32N | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CAMK2N1 | SNV | Missense_Mutation | novel | c.220N>T | p.Ala74Ser | p.A74S | Q7Z7J9 | protein_coding | tolerated_low_confidence(1) | benign(0.003) | TCGA-39-5040-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |